U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07778979) titled 'Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas' on Aug. 18.
Brief Summary: This substudy will investigate a new imaging approach using positron emission tomography (PET) and two investigational drugs ([18F]FET and [18F]FMISO) to see if the imaging results will help with the placement of catheters for therapy delivery in 20 adult patients with malignant gliomas (MGs) who are participating in the UAB IRB approved main study, A Phase I/II Study of Pembrolizumab and M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive and Newly Diagnosed Glioblastoma Multif...